Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Selected Publications

Environmental Cardiopulmonary Disease Group

Cytochrome P450

  1. Zeldin DC, Corcia A and Armstrong WM. (1985) Cyclic AMP-induced changes in membrane conductance of Necturus gallbladder epithelial cells. J Membr Biol, 84, 193-206. [Abstract]
  2. Capdevila JH, Wei S, Kumar A, Kobayashi J, Snapper JR, Zeldin DC, Bhatt RK and Falck JR. (1992) Resolution of dihydroxyeicosanoates and of dihydroxyeicosatrienoates by chiral phase chromatography. Anal Biochem, 207, 236-40. [Abstract]
  3. Zeldin DC, Kobayashi J, Falck JR, Winder BS, Hammock BD, Snapper JR and Capdevila JH. (1993) Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem, 268, 6402-7. [Abstract] [PDF]
  4. Bauer E, Guo Z, Ueng YF, Bell LC, Zeldin D and Guengerich FP. (1995) Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem Res Toxicol, 8, 136-42. [Abstract]
  5. Zeldin DC, DuBois RN, Falck JR and Capdevila JH. (1995) Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys, 322, 76-86. [Abstract]
  6. Zeldin DC, Plitman JD, Kobayashi J, Miller RF, Snapper JR, Falck JR, Szarek JL, Philpot RM and Capdevila JH. (1995) The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance. J Clin Invest, 95, 2150-60. [Abstract] [Full Text] [PDF]
  7. Zeldin DC, Wei S, Falck JR, Hammock BD, Snapper JR and Capdevila JH. (1995) Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis. Arch Biochem Biophys, 316, 443-51. [Abstract]
  8. Wu S, Moomaw CR, Tomer KB, Falck JR and Zeldin DC. (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem, 271, 3460-8. [Abstract] [Full Text] [PDF]
  9. Zeldin DC, Foley J, Ma J, Boyle JE, Pascual JM, Moomaw CR, Tomer KB, Steenbergen C and Wu S. (1996) CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol, 50, 1111-7. [Abstract] [PDF]
  10. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD and Wu S. (1996) Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys, 330, 87-96. [Abstract]
  11. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR and Zeldin DC. (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem, 272, 12551-9. [Abstract] [Full Text] [PDF]
  12. Zeldin DC, Foley J, Boyle JE, Moomaw CR, Tomer KB, Parker C, Steenbergen C and Wu S. (1997) Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology, 138, 1338-46. [Abstract] [Full Text] [PDF]
  13. Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, Moomaw CR, Tomer KB, Steenbergen C and Wu S. (1997) CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol, 51, 931-43. [Abstract]
  14. Luo G, Zeldin DC, Blaisdell JA, Hodgson E and Goldstein JA. (1998) Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Arch Biochem Biophys, 357, 45-57. [Abstract] [PDF]
  15. Ma J, Ramachandran S, Fiedorek FT, Jr. and Zeldin DC. (1998) Mapping of the CYP2J cytochrome P450 genes to human chromosome 1 and mouse chromosome 4. Genomics, 49, 152-5. [Abstract]
  16. Pascual JM, McKenzie A, Yankaskas JR, Falck JR and Zeldin DC. (1998) Epoxygenase metabolites of arachidonic acid affect electrophysiologic properties of rat tracheal epithelial cells. J Pharmacol Exp Ther, 286, 772-9. [Abstract] [Full Text] [PDF]
  17. Qu W, Rippe RA, Ma J, Scarborough P, Biagini C, Fiedorek FT, Travlos GS, Parker C and Zeldin DC. (1998) Nutritional status modulates rat liver cytochrome P450 arachidonic acid metabolism. Mol Pharmacol, 54, 504-13. [Abstract] [Full Text] [PDF]
  18. Schlezinger JJ, Parker C, Zeldin DC and Stegeman JJ. (1998) Arachidonic acid metabolism in the marine fish Stenotomus chrysops (Scup) and the effects of cytochrome P450 1A inducers. Arch Biochem Biophys, 353, 265-75. [Abstract]
  19. Chen J, Capdevila JH, Zeldin DC and Rosenberg RL. (1999) Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol, 55, 288-95. [Abstract] [Full Text] [PDF]
  20. Ma J, Qu W, Scarborough PE, Tomer KB, Moomaw CR, Maronpot R, Davis LS, Breyer MD and Zeldin DC. (1999) Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney. J Biol Chem, 274, 17777-88. [Abstract] [Full Text] [PDF]
  21. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC and Liao JK. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 285, 1276-9. [Abstract]
  22. Scarborough PE, Ma J, Qu W and Zeldin DC. (1999) P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev, 31, 205-34. [Abstract]
  23. Moran JH, Mitchell LA, Bradbury JA, Qu W, Zeldin DC, Schnellmann RG and Grant DF. (2000) Analysis of the cytotoxic properties of linoleic acid metabolites produced by renal and hepatic P450s. Toxicol Appl Pharmacol, 168, 268-79. [Abstract]
  24. Oleksiak MF, Wu S, Parker C, Karchner SI, Stegeman JJ and Zeldin DC. (2000) Identification, functional characterization, and regulation of a new cytochrome P450 subfamily, the CYP2Ns. J Biol Chem, 275, 2312-21. [Abstract] [Full Text] [PDF]
  25. Tsao CC, Foley J, Coulter SJ, Maronpot R, Zeldin DC and Goldstein JA. (2000) CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract. Mol Pharmacol, 58, 279-87. [Abstract] [Full Text] [PDF]
  26. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC and Kroetz DL. (2000) Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol, 57, 1011-20. [Abstract] [Full Text] [PDF]
  27. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC and Kroetz DL. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res, 87, 992-8. [Abstract] [Full Text] [PDF]
  28. Zeldin DC and Liao JK. (2000) Reply: cytochrome P450-derived eicosanoids and the vascular wall. Trends Pharmacol Sci, 21, 127-128. [Abstract]
  29. Zhu D, Bousamra M, 2nd, Zeldin DC, Falck JR, Townsley M, Harder DR, Roman RJ and Jacobs ER. (2000) Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries. Am J Physiol Lung Cell Mol Physiol, 278, L335-43. [Abstract]
  30. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI and Goldstein JA. (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 11, 597-607. [Abstract]
  31. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE and Bell DA. (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther, 299, 468-76. [Abstract]
  32. Jacobs ER and Zeldin DC. (2001) The lung HETEs (and EETs) up. Am J Physiol Heart Circ Physiol, 280, H1-H10 [Abstract] [Full Text]
  33. Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC and Liao JK. (2001) Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem, 276, 15983-9. [Abstract] [Full Text] [PDF]
  34. Qu W, Bradbury JA, Tsao CC, Maronpot R, Harry GJ, Parker CE, Davis LS, Breyer MD, Waalkes MP, Falck JR, Chen J, Rosenberg RL and Zeldin DC. (2001) Cytochrome P450 CYP2J9, a new mouse arachidonic acid omega-1 hydroxylase predominantly expressed in brain. J Biol Chem, 276, 25467-79. [Abstract] [Full Text] [PDF]
  35. Tsao CC, Coulter SJ, Chien A, Luo G, Clayton NP, Maronpot R, Goldstein JA and Zeldin DC. (2001) Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to regio- and stereoselective products. J Pharmacol Exp Ther, 299, 39-47. [Abstract]
  36. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK and Zeldin DC. (2001) Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol, 60, 310-20. [Abstract] [Full Text] [PDF]
  37. Zeldin DC. (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem, 276, 36059-62. [Abstract] [Full Text] [PDF]
  38. Zeldin DC, Wohlford-Lenane C, Chulada P, Bradbury JA, Scarborough PE, Roggli V, Langenbach R and Schwartz DA. (2001) Airway inflammation and responsiveness in prostaglandin H synthase-deficient mice exposed to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol, 25, 457-65. [Abstract]
  39. King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L, Spiecker M, Liao JK, Mohrenweiser H and Zeldin DC. (2002) Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol, 61, 840-52. [Abstract]
  40. Kroetz DL and Zeldin DC. (2002) Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol, 13, 273-83. [Abstract]
  41. Ma J, Bradbury JA, King L, Maronpot R, Davis LS, Breyer MD and Zeldin DC. (2002) Molecular cloning and characterization of mouse CYP2J6, an unstable cytochrome P450 isoform. Biochem Pharmacol, 64, 1447-60. [Abstract] [Full Text]
  42. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS and Liao JK. (2002) Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res, 90, 1020-7. [Abstract] [Full Text] [PDF]
  43. Wang JF, Yang Y, Sullivan MF, Min J, Cai J, Zeldin DC, Xiao YF and Morgan JP. (2002) Induction of cardiac cytochrome p450 in cocaine-treated mice. Exp Biol Med (Maywood), 227, 182-8. [Abstract]
  44. Zeldin DC. (2002) The 5-lipoxygenase pathway: a new therapeutic target for the treatment of pulmonary fibrosis. Am J Respir Crit Care Med, 165, 146-7. [Abstract]
  45. Oleksiak MF, Wu S, Parker C, Qu W, Cox R, Zeldin DC and Stegeman JJ. (2003) Identification and regulation of a new vertebrate cytochrome P450 subfamily, the CYP2Ps, and functional characterization of CYP2P3, a conserved arachidonic acid epoxygenase/19-hydroxylase. Arch Biochem Biophys, 411, 223-34. [Abstract] [Full Text]
  46. Pfister SL, Spitzbarth N, Zeldin DC, Lafite P, Mansuy D and Campbell WB. (2003) Rabbit aorta converts 15-HPETE to trihydroxyeicosatrienoic acids: potential role of cytochrome P450. Arch Biochem Biophys, 420, 142-52. [Abstract]
  47. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC and Grant DF. (2003) Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol, 64, 482-90 [Abstract] [Full Text] [PDF]
  48. Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW and Zeldin DC. (2003) Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther, 307, 753-64. [Abstract] [Full Text] [PDF]
  49. Yaghi A, Bradbury JA, Zeldin DC, Mehta S, Bend JR and McCormack DG. (2003) Pulmonary cytochrome P-450 2J4 is reduced in a rat model of acute Pseudomonas pneumonia. Am J Physiol Lung Cell Mol Physiol, 285, L1099-105. [Abstract]
  50. Zhao X, Pollock DM, Inscho EW, Zeldin DC and Imig JD. (2003) Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension, 41, 709-14. [Abstract] [Full Text] [PDF]
  51. Zhao X, Pollock DM, Zeldin DC and Imig JD. (2003) Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension, 42, 775-80. [Abstract] [Full Text] [PDF]
  52. DeLozier TC, Tsao CC, Coulter SJ, Foley J, Bradbury JA, Zeldin DC and Goldstein JA. (2004) CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther, 310, 845-54. [Abstract] [Full Text] [PDF]
  53. Ma J, Graves J, Bradbury JA, Zhao Y, Swope DL, King L, Qu W, Clark J, Myers P, Walker V, Lindzey J, Korach KS and Zeldin DC. (2004) Regulation of mouse renal CYP2J5 expression by sex hormones. Mol Pharmacol, 65, 730-43 [Abstract] [Full Text] [PDF]
  54. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM and Nebert DW. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14, 1-18. [Abstract]
  55. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, Gooch R, Foley J, Newman J, Mao L, Rockman HA, Hammock BD, Murphy E and Zeldin DC. (2004) Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res, 95, 506-14. [Abstract] [Full Text] [PDF]
  56. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Borgel J, Mugge A, Lindpaintner K, Huesing A, Maisch B, Zeldin DC and Liao JK. (2004) Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation, 110, 2132-6. [Abstract] [Full Text] [PDF]
  57. Wang H, Zhao Y, Bradbury JA, Graves JP, Foley J, Blaisdell JA, Goldstein JA and Zeldin DC. (2004) Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Mol Pharmacol, 65, 1148-58. [Abstract] [Full Text] [PDF]
  58. Xiao YF, Ke Q, Seubert JM, Bradbury JA, Graves J, Degraff LM, Falck JR, Krausz K, Gelboin HV, Morgan JP and Zeldin DC. (2004) Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol, 66, 1607-16. [Abstract] [Full Text] [PDF]
  59. Yaghi A, Bend JR, Webb CD, Zeldin DC, Weicker S, Mehta S and McCormack DG. (2004) Excess nitric oxide decreases cytochrome P-450 2J4 content and P-450-dependent arachidonic acid metabolism in lungs of rats with acute pneumonia. Am J Physiol Lung Cell Mol Physiol, 286, L1260-7. [Abstract]
  60. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC and Boerwinkle E. (2005) The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet, 14, 2829-37. [Abstract] [Full Text] [PDF]
  61. Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC and Wang DW. (2005) Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res, 65, 4707-15. [Abstract] [Full Text] [PDF]
  62. King LM, Gainer JV, David GL, Dai D, Goldstein JA, Brown NJ and Zeldin DC. (2005) Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics, 15, 7-13. [Abstract]
  63. Seubert JM, Xu F, Graves JP, Collins JB, Sieber SO, Paules RS, Kroetz DL and Zeldin DC. (2005) Differential renal gene expression in prehypertensive and hypertensive spontaneously hypertensive rats. Am J Physiol Renal Physiol, 289, F552-61. [Abstract]
  64. Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW and Zeldin DC. (2005) Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther, 314, 522-32. [Abstract] [Full Text] [PDF]
  65. Gaedigk A, Baker DW, Totah RA, Gaedigk R, Pearce RE, Vyhlidal CA, Zeldin DC and Leeder JS. (2006) Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther, 319, 523-32. [Abstract]
  66. Lafite P, Dijols S, Buisson D, Macherey AC, Zeldin DC, Dansette PM and Mansuy D. (2006) Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett, 16, 2777-80. [Abstract] [Full Text] [PDF]
  67. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKCa channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H491-H499. [Abstract] [Full Text] [PDF]
  68. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Hum Mol Genet. 2006 May 15;15(10):1640-1649. [Abstract] [Full Text] [PDF]
  69. Lu T, Ye D, Wang X, Seubert J.M, Graves J, Bradbury JA, Zeldin DC, Lee HC. Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol. 2006 Sep 1;575(Pt 2):627-644. [Abstract] [Full Text] [PDF]
  70. Paine MF, Hart HL, Lundington SS, Haining RL, Rettie AE, Zeldin D.C. The human intestinal cytochrome P450 Pie. Drug Metab Dispos. 2006 May;34(5):880-886. [Abstract] [Full Text] [PDF]
  71. Seubert JM, Sinal CJ, Graves JP, DeGraff LM, Bradbury JS, Lee CR, Goralski KB, Carey MA, Lauria A, Newman JW, Hammock BD, Falck JR, Roberts H, Rockman HA, Murphy E, Zeldin DC. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res. 2006 Aug 18;99(4):442-450. [Abstract] [Full Text] [PDF]
  72. Wang MS, Saulter JY, Usuki E, Cheung YL, Hall M, Bridges AS, Loewen G, Parkinson OT, Stephens CE, Allen JL, Zeldin DC, Boykin DW, Tidwell RR, Parkinson A, Paine MF, Hall JE. CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos. 2006 Dec;34(12):1985-1994. [Abstract] [Full Text] [PDF]
  73. DeLozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, Goldstein JA. Detection of human CYP2C8, CYP2C9 and CYP2J2 in cardiovascular tissues. Drug Metabolism and Disposition 2007; 35:682-688. [Abstract]
  74. Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, Card JW, Wang J, Zeldin DC and Wang DW. (2007) Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res, 67, 6665-74. [Abstract]
  75. Ke Q, Xiao Y-F, Bradvury JA, Graves JP, DeGraff LM, Seubert JM, Zeldin DC. Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice. Mol Pharmacol. 2007 Oct;72(4):11063-73. [Abstract] [Full Text] [PDF]
  76. Lafite P, André F, Zeldin DC, Dansette PM, Mansuy D. Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry. 2007 Sep 11;46(36): 10237-47. [Abstract] [Full Text] [PDF]
  77. Lafite P, Dijols S, Zeldin DC, Dansette PM and Mansuy D. (2007) Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch Biochem Biophys, 464, 155-68. [Abstract]
  78. Nüsing RM, Schweer H, Fleming I, Zeldin DC, Wegmann M. Epoxyeicosatrienoic acids affect electrolyte transport in renal tubular epithelial cells: Dependence on cyclooxygenase and cell polarity. Am J Physiol Renal Physiol. 2007 Jul;293(1):F288-98. [Abstract] [Full Text] [PDF]
  79. Seubert JM, Zeldin DC, Nithipatikom K and Gross GJ. (2007) Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat, 82, 50-9. [Abstract]
  80. Wang MZ, Wu JQ, Bridges AS, Zeldin DC, Kornbluth S, Tidwell RR, Hall JE, Paine MF. Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos. 2007 Nov;35(11):2067-75. [Abstract] [Full Text] [PDF]
  81. Yang S, Lin L, Chen J-X, Lee CR, Seubert JM, Wang Y, Wang H, Chao Z-R, Tao D-D, Gong J-P, Lu Z-Y, Wang DW, Zeldin DC. Cytochrome P450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-α via MAPK and PI3K/Akt signaling pathways. AmericanJ Physiol Heart Circ Physiol. 2007 Jul;293(1)H142-51. [Abstract] [Full Text]
  82. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics. 2007 May;17(5):349-58. [Abstract] [Full Text] [PDF]
  83. Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, Imig JD, Pedersen TL, Newman JW, Hammock BD, Conley AJ, Korach KS, Coffman TM and Zeldin DC. (2008) Increased blood pressure in mice lacking cytochrome P450 2J5. Faseb J, 22, 4096-108. [Abstract]
  84. Larsen BT, Gutterman DD, Sato A, Toyama K, Campbell WB, Zeldin DC, Falck JR, Miura H. Hydrogen peroxide inhibits cytochrome P450 epoxygenases: Interaction between two endothelium-derived hyperpolarizing factors. Circ Res. 2008 Jan 4;102(1):59-67. [Abstract] [Full Text] [PDF]
  85. Moshal KS, Zeldin DC, Sithu SD, Sen U, Tyagi N, Kumar M, Hughes WM, Metreveli N, Rosenberger DSE, Singh M, Vacek TP, Rodriguez WE, Ayotunde A, Tyagi SC. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-k(beta) in hyperhomocysteinemia. J Cell Physiol. 2008 Jun;215(3):771-81. [Abstract] [Full Text] [PDF]
  86. Nayeem MA, Poloyac SM, Falck JR, Zeldin DC, Ledent C, Ponnoth DS, Ansari HR, Mustafa SJ. Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice. Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2068-78. [Abstract] [Full Text]
  87. van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH and Schinkel AH. (2008) Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol, 73, 1029-36. [Abstract]
  88. Zhang L, Ding H, Yan J, Hui R, Wang W, Kissling GE, Zeldin DC, Wang DW. Genetic variation in cytochrome P450 2J2 and soluble expoxide hydrolase and the risk of ischemic stroke in a Chinese cohort. Pharmacogenetics and Genomics 2008; 18:45-51. [Abstract]
  89. Baragatti B, Laniado-Schwartzman M, Angeloni D, Scebba F, Ciofini E, Sodini D, Ottaviano V, Nencioni S, Paolicchi A, Graves JP, Zeldin DC, Gotlinger K, Luin S, Coceani F. EDHF function in the ductus arteriosus: Evidence against involvement of epoxyeicosatrienoic acids (EETs) and 12S-hydroxyeicosatrienoic acid (12S-HETE). Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):2161-8. [Abstract] [Full Text]
  90. Bodiga S, Zhang R, Jacobs DE, Larsen BT, Tampo A, Manthati VL, Kwok WM, Zeldin DC, Falck JR, Gutterman DD, Jacobs ER and Medhora MM. (2009) Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels. J Mol Cell Cardiol, 46, 978-88. [Abstract]
  91. Chaudhary KR, Batchu SN, Graves JP, Das D, Suresh MR, Zeldin DC, Seubert JS. Role of B-type natriuretic peptide in epoxyeicosatrienoic acid mediated improved postischemic recovery of heart contractile function. Cardiovasc Res. 2009 July 15;83(2):362-70. [Abstract] [Full Text] [PDF]
  92. Chen C, Li G, Liao W, Wu J, Liu L, Ma D, Zhou J, Elbekai RH, Edin ML, Zeldin DC, Wang DW. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther. 2009 Jun;329(3):908-18. [Abstract] [Full Text] [PDF]
  93. Homma S, Koido S, Sagawa Y, Suzuki H, Komita H, Nagasaki E, Takahara A, Horiguchi-Yamada J, Tajiri H, Zeldin DC, Obata T. Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity. Clin Exp Immunol. 2009 May;156(2):344-52. [Abstract] [Full Text] [PDF]
  94. Iliff JJ, Wang R, Zeldin DC, Alkayed NJ. Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels. Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1352-63. [Abstract] [Full Text]
  95. Nayeem M, Ponnoth D, Boegehold M, Zeldin DC, Falck JR, Mustafa SJ. High salt diet enhances mouse aortic relaxation through adenosine A2A receptor via CYP epoxygenases. Am J Physiol Regul Integr Comp Physiol. 2009 Mar;296(3):R567-74. [Abstract] [Full Text]
  96. Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, DeGraff LM, Bradbury JA, Holness MJ, Warner TD, Bishop-Bailey D. The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha; in vitro and in vivo. PLoS One. 2009 Oct 12;4(10):e7421. [Abstract] [Full Text] [PDF]
  97. Zhang Y, El-Sikhry H, Chaudhary K, Batchu SN, Shayeqanpour A, Jukar TO, Bradbury JA, Graves JP, DeGraff LM, Myers PH, Rouse DC, Foley J, Nyska A, Zeldin DC, Seubert JM. Overexpression of CYP2J2 provides protection against doxorubicin induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H37-46. [Abstract] [Full Text]
  98. Cheng LM, Jiang JG, Sun ZY, Chen C, Dackor RT, Zeldin DC, Wang DW. The epoxyeicosatrienoic acid-stimulated proliferation of EGF-R involves activation of metalloproteinases and release of HB-EGF in cancer cells. Acta Pharmacol Sin. 2010 Feb;31(2):211-18. [Abstract] [Full Text] [PDF]
  99. Ding H, Zhang L, Wu B, Wang Q, Hui R, Wang W, Dackor RT, Kissling GE, Zeldin DC, Wang DW. Association of common variants of CYP4A11 and CYP4F2 with stroke in the Chinese Han population. Pharmacogenetics and Genomics 2010; 20:187-194. [Abstract]
  100. Kim DH, Vanella L, Inoue K, Burgess A, Gotlinger K, Manthati VL, Koduru SR, Zeldin DC, Falck JR, Schwartzman ML, Abraham NG. 2010. Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARgamma. Stem Cells Dev 19(12):1863-1873. [Abstract]
  101. Konno Y, Kamino H, Moore R, Lih F, Tomer KB, Zeldin DC, Goldstein JA and Negishi M. (2010) The nuclear receptors constitutive active/androstane receptor and pregnane x receptor activate the Cyp2c55 gene in mouse liver. Drug Metab Dispos, 38, 1177-82. [Abstract]
  102. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow L, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. The FASEB journal. 2010 24(10):3770-81. [Abstract] [Full Text] [PDF]
  103. Nayeem MA, Zeldin DC, Boegehold MA, Morisseau C, Marowsky A, Ponnoth DS, Roush KP, Falck JR. Modulation by salt intake of the vascular response mediated through adenosine A2A receptor: Role of CYP epoxygenase and soluble epoxide hydrolase. Am J Physiol Regul Integr Comp Physiol. 2010 Jul;299(1):R325-33. [Abstract]
  104. Zheng C, Wang L, Li R, Ma B, Tu L, Xu X, Dackor RT, Zeldin DC, Wang DW. Gene delivery of a cytochrome P450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. Am J Respir Cell Mol Biol. 2010 Jan 29; [Abstract]
  105. Bystrom J, Wray JA, Sugden MC, Holness MJ, Swales KE, Warner TD, Edin ML, Zeldin DC, Gilroy DW and Bishop-Bailey D. (2011) Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One, 6, e26591. [Abstract]
  106. Chen C, Wei X, Rao X, Wu J, Yang S, Chen F, Ma D, Zhou J, Dackor RT, Zeldin DC, Wang DW. CYP2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. The Journal of pharmacology and experimental therapeutics. 2011 336(2):344-355. [Abstract] [Full Text] [PDF]
  107. Chen G, Wang P, Xu G, Gruzdev A, Zeldin DC, Wang DW. Cytochrome P450 Epoxygenase CYP2J2 Attenuates Nephropathy in Streptozotocin-induced Diabetic Mice. Prostaglandins & other lipid mediators. 2011 96(1-4):63-71. [Abstract]
  108. Dackor RT, Cheng J, Voltz JW, Card JW, Ferguson CD, Garrett RC, Bradbury JA, DeGraff LM, Lih FB, Tomer KB, Flake GP, Travlos GS, Ramsey RW, Jr., Edin ML, Morgan DL and Zeldin DC. (2011) Prostaglandin E(2) protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction. Am J Physiol Lung Cell Mol Physiol, 301, L645-55. [Abstract]
  109. Deng, Y., M.L. Edin, K.N. Theken, R.N. Schuck, G.P. Flake, M.A. Kannon, L.M. DeGraff, F.B. Lih, J. Foley, J.A. Bradbury, J.P. Graves, K.B. Tomer, J.R. Falck, D.C. Zeldin, C.R. Lee. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. The FASEB journal, 25(2):703-713, 2011. [Abstract]
  110. Edin ML, Wang Z, Bradbury JA, Graves JP, Lih FB, DeGraff LM, Foley JA, Torphy R, Ronnekleiv OK, Tomer KB, Lee CR, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. The FASEB journal. 2011 25(10):3436-3447. [Abstract] [Full Text]
  111. Lee CR, Pretorius M, Schuck RN, Burch LH, Bartless J, Williams SM, Zeldin DC, Brown NJ. Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) is Associated with Forearm Vasoodilator Responses in Humans. Hypertension. 2011 57(1):116-122. [Abstract] [Full Text] [PDF]
  112. Xiao B, Yan J, Xiao X, Voltz JW, Zeldin DC, Wang DW. Overexpression of Cytochrome P450 Epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther. 2010 Sep 10;334(3):784-94. [Abstract] [Full Text] [PDF]
  113. Xu X, Zhao CX, Wang L, Tu L, Fang X, Zheng C, Edin ML, Zeldin DC, Wang DW. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes. 2010 Apr;59(4):997-1005. [Abstract] [Full Text] [PDF]
  114. Liu L, Chen C, Gong W, Li Y, Edin ML, Zeldin DC and Wang DW. (2011) Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther, 339, 451-63. [Abstract]
  115. Nayeem MA, Zeldin DC, Boegehold MA, Falck JR. Salt modulates vascular response through adenosine A(2A) receptor in eNOS-null mice: role of CYP450 epoxygenase and soluble epoxide hydrolase. Molecular and cellular biochemistry. 2011 350(1-2):101-111. [Abstract] [Full Text] [PDF]
  116. Panigrahy D, Greene ER, Pozzi A, Wang DW and Zeldin DC. (2011) EET signaling in cancer. Cancer Metastasis Rev, 30, 525-40. [Abstract]
  117. Spector AA, Campbell WB and Zeldin DC. (2011) Eicosanoids and disease. Introduction. Prostaglandins Other Lipid Mediat, 96, 1-2. [Abstract]
  118. Uehara S, Murayama N, Nakanish Y, Zeldin DC, Yamazaki H, Uno Y. Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. Journal of Pharmacology and Experimental Therapeutics. 2011 339(2):654-661. [Abstract]
  119. Chen G, Xu R, Wang Y, Wang P, Zhao G, Xu X, Gruzdev A, Zeldin DC and Wang DW. (2012) Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy. Am J Physiol Endocrinol Metab, 303, E563-75. [Abstract]
  120. Decker M, Adamska M, Cronin A, Di Giallonardo F, Burgener J, Marowsky A, Falck JR, Morisseau C, Hammock BD, Gruzdev A, Zeldin DC and Arand M. (2012) EH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides. J Lipid Res, 53, 2038-45. [Abstract]
  121. Jiang H, Harrison FE, Jain K, Benjamin S, May JM, Graves JP, Zeldin DC, Falck JR, Hammock BD and McGiff JC. (2012) Vitamin C activation of the biosynthesis of epoxyeicosatrienoic acids. Adv Biosci Biotechnol, 3, 204-218. [Abstract]
  122. Li R, Xu X, Chen C, Yu X, Edin ML, DeGraff LM, Lee CR, Zeldin DC, Wang DW. Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice. Prostaglandins & other lipid mediators 2012 99(3-4):68-78. [Abstract]
  123. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnes CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW and Zeldin DC. (2012) Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest, 122, 178-91. [Abstract]
  124. Ponnoth DS, Nayeem MA, Kunduri SS, Tilley SL, Zeldin DC, Ledent C and Mustafa SJ. (2012) Role of omega-hydroxylase in adenosine-mediated aortic response through MAP kinase using A2A-receptor knockout mice. Am J Physiol Regul Integr Comp Physiol, 302, R400-8. [Abstract]
  125. Ruparel S, Henry MA, Akopian A, Patil M, Zeldin DC, Roman L and Hargreaves KM. (2012) Plasticity of cytochrome P450 isozyme expression in rat trigeminal ganglia neurons during inflammation. Pain, 153, 2031-9. [Abstract]
  126. Zhao G, Wang J, Xu X, Jing Y, Tu L, Li X, Chen C, Cianflone K, Wang P, Dackor RT, Zeldin DC and Wang DW. (2012) Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-alpha-induced injury. J Lipid Res, 53, 456-66. [Abstract]
  127. Theken KN, Schuck RN, Edin ML, Tran B, Ellis K, Bass A, Lih FB, Tomer KB, Poloyac SM, Wu MC, Hinderliter AL, Zeldin DC, Stouffer GA and Lee CR. (2012) Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis, 222, 530-6. [Abstract]
  128. Askari A, Thomson SJ, Edin ML, Zeldin DC and Bishop-Bailey D. (2013) Roles of the epoxygenase CYP2J2 in the endothelium. Prostaglandins Other Lipid Mediat, 107, 56-63. [Abstract]
  129. Bystrom J, Thomson SJ, Johansson J, Edin ML, Zeldin DC, Gilroy DW, Smith AM and Bishop-Bailey D. (2013) Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease? PLoS One, 8, e75107. [Abstract]
  130. Chai Q, Wang XL, Zeldin DC and Lee HC. (2013) Role of caveolae in shear stress-mediated endothelium-dependent dilation in coronary arteries. Cardiovasc Res, 100, 151-9. [Abstract]
  131. Chaudhary KR, Zordoky BN, Edin ML, Alsaleh N, El-Kadi AO, Zeldin DC, Seubert JM. Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice. Prostaglandins & other lipid mediators. 2013 104-105:8-17. [Abstract]
  132. Graves JP, Edin ML, Bradbury JA, Gruzdev A, Cheng J , Lih FB , Masinde TA, Qu W, Clayton NP, Morrison JP, Tomer KB, Zeldin DC. Characterization of Four New Mouse Cytochrome P450 Enzymes of the CYP2J Subfamily. Drug metabolism and disposition: the biological fate of chemicals 2013 41(4):763-773. [Abstract]
  133. Klett EL, Chen S, Edin ML, Li LO, Ilkayeva O, Zeldin DC, Newgard CB and Coleman RA. (2013) Diminished acyl-CoA synthetase isoform 4 activity in INS 832/13 cells reduces cellular epoxyeicosatrienoic acid levels and results in impaired glucose-stimulated insulin secretion. J Biol Chem, 288, 21618-29. [Abstract]
  134. Ma B, Xiong X, Chen C, Li H, Xu X, Li X, Li R, Chen G, Dackor RT, Zeldin DC and Wang DW. (2013) Cardiac-specific overexpression of CYP2J2 attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice. Endocrinology, 154, 2843-56. [Abstract]
  135. Ma F, Lin F, Chen C, Cheng J, Zeldin DC, Wang Y and Wang DW. (2013) Indapamide lowers blood pressure by increasing production of epoxyeicosatrienoic acids in the kidney. Mol Pharmacol, 84, 286-95. [Abstract]
  136. Nayeem MA, Pradhan I, Mustafa SJ, Morisseau C, Falck JR and Zeldin DC. (2013) Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARgamma. Am J Physiol Regul Integr Comp Physiol, 304, R23-32. [Abstract]
  137. Oni-Orisan A, Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC and Lee CR. (2013) Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. Prostaglandins Other Lipid Mediat, 104-105, 67-73. [Abstract]
  138. Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J, Edin ML, Lee CR, Benny O, Mudge DK, Butterfield CE, Mammoto A, Mammoto T, Inceoglu B, Jenkins RL, Simpson MA, Akino T, Lih FB, Tomer KB, Ingber DE, Hammock BD, Falck JR, Manthati VL, Kaipainen A, D'Amore PA, Puder M, Zeldin DC and Kieran MW. (2013) Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A, 110, 13528-33. [Abstract]
  139. Schuck RN, Theken KN, Edin ML, Caughey M, Bass A, Ellis K, Tran B, Steele S, Simmons BP, Lih FB, Tomer KB, Wu MC, Hinderliter AL, Stouffer GA, Zeldin DC and Lee CR. (2013) Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis, 227, 442-8. [Abstract]
  140. Strauss KI, Gruzdev A and Zeldin DC. (2013) Altered behavioral phenotypes in soluble epoxide hydrolase knockout mice: effects of traumatic brain injury. Prostaglandins Other Lipid Mediat, 104-105, 18-24. [Abstract]
  141. Westphal C, Spallek B, Konkel A, Marko L, Qadri F, DeGraff LM, Schubert C, Bradbury JA, Regitz-Zagrosek V, Falck JR, Zeldin DC, Muller DN, Schunck WH and Fischer R. (2013) CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy. PLoS One, 8, e73490. [Abstract]
  142. Zhang W, Davis CM, Edin ML, Lee CR, Zeldin DC and Alkayed NJ. (2013) Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. PLoS One, 8, e61244. [Abstract]
  143. Abraham NG, Sodhi K, Silvis AM, Vanella L, Favero G, Rezzani R, Lee C, Zeldin DC and Schwartzman ML. (2014) CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype. Hypertension, 64, 1352-61. [Abstract]
  144. Askari AA, Thomson S, Edin ML, Lih FB, Zeldin DC and Bishop-Bailey D. (2014) Basal and inducible anti-inflammatory epoxygenase activity in endothelial cells. Biochem Biophys Res Commun, 446, 633-7. [Abstract]
  145. Cheng J, Edin ML, Hoopes SL, Li H, Bradbury JA, Graves JP, DeGraff LM, Lih FB, Garcia V, Shaik JS, Tomer KB, Flake GP, Falck JR, Lee CR, Poloyac SM, Schwartzman ML, Zeldin DC. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2014 28(7):2915-2931. [Abstract]
  146. Lee KS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC and Hammock BD. (2014) Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem, 57, 7016-30. [Abstract]
  147. Pradhan I, Zeldin DC, Ledent C, Mustafa JS, Falck JR and Nayeem MA. (2014) High salt diet exacerbates vascular contraction in the absence of adenosine A(2)A receptor. J Cardiovasc Pharmacol, 63, 385-94. [Abstract]
  148. Schuck RN, Zha W, Edin ML, Gruzdev A, Vendrov KC, Miller TM, Xu Z, Lih FB, DeGraff LM, Tomer KB, Jones HM, Makowski L, Huang L, Poloyac SM, Zeldin DC and Lee CR. (2014) The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS One, 9, e110162. [Abstract]
  149. Shao Z, Fu Z, Stahl A, Joyal JS, Hatton C, Juan A, Hurst C, Evans L, Cui Z, Pei D, Gong Y, Xu D, Tian K, Bogardus H, Edin ML, Lih F, Sapieha P, Chen J, Panigrahy D, Hellstrom A, Zeldin DC and Smith LE. (2014) Cytochrome P450 2C8 omega3-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization--brief report. Arterioscler Thromb Vasc Biol, 34, 581-6. [Abstract]
  150. Uehara S, Murayama N, Nakanishi Y, Nakamura C, Hashizume T, Zeldin DC, Yamazaki H and Uno Y. (2014) Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. Xenobiotica, 44, 769-74. [Abstract]
  151. Wang WH, Zhang C, Lin DH, Wang L, Graves JP, Zeldin DC, Capdevila JH. Cyp2c44 epoxygenase in the collecting duct is essential for the high K+ intake-induced antihypertensive effect. American journal of physiology. Renal physiology 2014 307(4):F453-F460. [Abstract]
  152. Wang X, Ni L, Yang L, Duan Q, Chen C, Edin ML, Zeldin DC, Wang DW. CYP2J2-Derived Epoxyeicosatrienoic Acids Suppress Endoplasmic Reticulum Stress in Heart Failure. Journal of lipid research 2014 85(1):105-115. [Abstract]
  153. Zha W, Edin ML, Vendrov KC, Schuck RN, Lih FB, Jat JL, Bradbury JA, DeGraff LM, Hua K, Tomer KB, Falck JR, Zeldin DC and Lee CR. (2014) Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity. J Lipid Res, 55, 2124-36. [Abstract]
  154. Chen G, Xu R, Zhang S, Wang Y, Wang P, Edin ML, Zeldin DC and Wang DW. (2015) CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice. Am J Physiol Endocrinol Metab, 308, E97-E110. [Abstract]
  155. Dai M, Wu L, He Z, Zhang S, Chen C, Xu X, Wang P, Gruzdev A, Zeldin DC, Wang DW. Epoxyeicosatrienoic acids regulate macrophage polarization and prevent LPS-induced cardiac dysfunction. Journal of cellular physiology 2015 230(9):2108-2119. [Abstract]
  156. Graves JP, Gruzdev A, Bradbury JA, DeGraff LM, Li H, House JS, Hoopes SL, Edin ML and Zeldin DC. (2015) Quantitative Polymerase Chain Reaction Analysis of the Mouse Cyp2j Subfamily: Tissue Distribution and Regulation. Drug Metab Dispos, 43, 1169-80. [Abstract]
  157. He Z, Zhang X, Chen C, Wen Z, Hoopes SL, Zeldin DC, Wang DW. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II. Circulation Research 2015 105(3):304-317. [Abstract]
  158. Hoopes SL, Garcia V, Edin ML, Schwartzman ML and Zeldin DC. (2015) Vascular actions of 20-HETE. Prostaglandins & other lipid mediators 120():9-16.  [Abstract]
  159. Kirkby NS, Reed DM, Edin ML, Rauzi F, Mataragka S, Vojnovic I, Bishop-Bailey D, Milne GL, Longhurst H, Zeldin DC, Mitchell JA and Warner TD. Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. Circulation 2015 29(11):4568-4578 [Abstract]
  160. Li P, Lahvic JL, Binder V, Pugach EK, Riley EB, Tamplin OJ, Panigrahy D, Bowman TV, Barrett FG, Heffner GC, McKinney-Freeman S, Schlaeger TM, Daley GQ, Zeldin DC and Zon LI. (2015) Epoxyeicosatrienoic acids enhance embryonic haematopoiesis and adult marrow engraftment. Nature, 523, 468-71. [Abstract]
  161. Li R, Xu X, Chen C, Wang Y, Gruzdev A, Zeldin DC and Wang DW. (2015) CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARgamma. Am J Physiol Endocrinol Metab, 308, E270-82. [Abstract]
  162. Thomson S, Edin ML, Lih FB, Davies M, Yaqoob MM, Hammock BD, Gilroy D, Zeldin DC and Bishop-Bailey D. (2015) Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins. Biochem Biophys Res Commun, 463, 774-80. [Abstract]
  163. Uehara S, Murayama N, Nakanishi Y, Nakamura C, Hashizume T, Zeldin DC, Yamazaki H, Uno Y. Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine. Xenobiotica; the fate of foreign compounds in biological systems 2015 45(2):124-130. [Abstract]
  164. Vanella L, Canestraro M, Lee CR, Cao J, Zeldin DC, Schwartzman ML and Abraham NG. (2015) Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis. Prostaglandins Other Lipid Mediat, 120, 139-47. [Abstract]
  165. Yang L, Ni L, Duan Q, Wang X, Chen C, Chen S, Chaugai S, Zeldin DC, Tang JR and Wang DW. (2015) CYP epoxygenase 2J2 prevents cardiac fibrosis by suppression of transmission of pro-inflammation from cardiomyocytes to macrophages. Prostaglandins Other Lipid Mediat, 116-117, 64-75. [Abstract]
  166. Zhang S, Chen G, Li N, Dai M, Chen C, Wang P, Tang H, Hoopes SL, Zeldin DC, Wang DW and Xu X. (2015) CYP2J2 overexpression ameliorates hyperlipidemia via increased fatty acid oxidation mediated by the AMPK pathway. Obesity (Silver Spring), 23, 1401-13. [Abstract]
  167. Gilroy DW, Edin ML, De Maeyer RP, Bystrom J, Newson J, Lih FB, Stables M, Zeldin DC and Bishop-Bailey D. (2016) CYP450-derived oxylipins mediate inflammatory resolution. Proc Natl Acad Sci U S A, 113, E3240-9. [Abstract]
  168. Gong Y, Fu Z, Edin ML, Liu CH, Wang Z, Shao Z, Fredrick TW, Saba NJ, Morss PC, Burnim SB, Meng SS, Lih FB, Lee KS, Moran EP, SanGiovanni JP, Hellstrom A, Hammock BD, Zeldin DC and Smith LE. (2016) Cytochrome P450 Oxidase 2C Inhibition Adds to omega-3 Long-Chain Polyunsaturated Fatty Acids Protection Against Retinal and Choroidal Neovascularization. Arterioscler Thromb Vasc Biol, 36, 1919-27. [Abstract] 
  169. Gong Y, Shao Z, Fu Z, Edin ML, Sun Y, Liegl RG, Wang Z, Liu CH, Burnim SB, Meng SS, Lih FB, SanGiovanni JP, Zeldin DC, Hellstrom A and Smith LE. (2016) Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine, 13, 201-211. [Abstract] 
  170. Hanif A, Edin ML, Zeldin DC, Morisseau C and Nayeem MA. (2016) Effect of Soluble Epoxide Hydrolase on the Modulation of Coronary Reactive Hyperemia: Role of Oxylipins and PPARgamma. PLoS One, 11, e0162147. [Abstract] 
  171. Hanif A, Edin ML, Zeldin DC, Morisseau C and Nayeem MA. (2016) Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart: role of oxylipins and PPARgamma. Am J Physiol Regul Integr Comp Physiol, 311, R676-R688. [Abstract] 
  172. Jia J, Davis CM, Zhang W, Edin ML, Jouihan S, Jia T, Bradbury JA, Graves JP, DeGraff LM, Lee CR, Ronnekleiv O, Wang R, Xu Y, Zeldin DC and Alkayed NJ. (2016) Sex- and isoform-specific mechanism of neuroprotection by transgenic expression of P450 epoxygenase in vascular endothelium. Exp Neurol, 279, 75-85. [Abstract] 
  173. Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC and Lee CR. (2016) Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. J Lipid Res, 57, 109-19. [Abstract] 
  174. Rauzi F, Kirkby NS, Edin ML, Whiteford J, Zeldin DC, Mitchell JA and Warner TD. (2016) Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1. FASEB J, 30, 4256-4266. [Abstract] 
  175. Wells MA, Vendrov KC, Edin ML, Ferslew BC, Zha W, Nguyen BK, Church RJ, Lih FB, DeGraff LM, Brouwer KL, Barritt ASt, Zeldin DC and Lee CR. (2016) Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis. Prostaglandins Other Lipid Mediat, 125, 19-29. [Abstract] 
  176. Xu X, Li R, Chen G, Hoopes SL, Zeldin DC and Wang DW. (2016) The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases. Adv Nutr, 7, 1122-1128. [Abstract] 
  177. Yadav VR, Hong KL, Zeldin DC and Nayeem MA. (2016) Vascular endothelial over-expression of soluble epoxide hydrolase (Tie2-sEH) enhances adenosine A1 receptor-dependent contraction in mouse mesenteric arteries: role of ATP-sensitive K+ channels. Mol Cell Biochem, 422, 197-206. [Abstract] 
  178. Bettaieb A, Koike S, Chahed S, Zhao Y, Bachaalany S, Hashoush N, Graham J, Fatima H, Havel PJ, Gruzdev A, Zeldin DC, Hammock BD and Haj FG. (2017) Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury. FEBS J. [Abstract] 
  179. Garcia V, Gilani A, Shkolnik B, Pandey V, Zhang FF, Dakarapu R, Gandham SK, Reddy NR, Graves JP, Gruzdev A, Zeldin DC, Capdevila JH, Falck JR and Schwartzman ML. (2017) 20-HETE Signals Through G-Protein-Coupled Receptor GPR75 (Gq) to Affect Vascular Function and Trigger Hypertension. Circ Res, 120, 1776-1788. [Abstract] 
  180. Graves JP, Gruzdev A, Bradbury JA, DeGraff LM, Edin ML and Zeldin DC. (2017) Quantitative Polymerase Chain Reaction Analysis of the Mouse Cyp2c Subfamily and Characterization of their Tissue Distribution. Drug Metab Dispos. [Abstract] 
  181. Hanif A, Edin ML, Zeldin DC, Morisseau C, Falck JR and Nayeem MA. (2017) Vascular endothelial overexpression of human CYP2J2 (Tie2-CYP2J2 Tr) modulates cardiac oxylipin profiles and enhances coronary reactive hyperemia in mice. PLoS One, 12, e0174137. [Abstract] 
  182. Hanif A, Edin ML, Zeldin DC, Morisseau C, Falck JR and Nayeem MA. (2017) Vascular Endothelial Over-Expression of Human Soluble Epoxide Hydrolase (Tie2-sEH Tr) Attenuates Coronary Reactive Hyperemia in Mice: Role of Oxylipins and omega-Hydroxylases. PLoS One, 12, e0169584. [Abstract] 
  183. Hoopes SL, Gruzdev A, Edin ML, Graves JP, Bradbury JA, Flake GP, Lih FB, DeGraff LM and Zeldin DC. (2017) Generation and characterization of epoxide hydrolase 3 (EPHX3)-deficient mice. PLoS One, 12, e0175348. [Abstract] 
  184. Hu J, Geyer A, Dziumbla S, Awwad K, Zeldin DC, Schunck WH, Popp R, Fromel T and Fleming I. (2017) Prostaglandins and Other Lipid Mediators (POLM), Special Issue of the 6th European workshop on lipid mediators: Role of Muller cell cytochrome P450 2c44 in murine retinal angiogenesis. Prostaglandins Other Lipid Mediat. [Abstract] 

COX-derived Eicosanoids

  1. Boyle JE, Lindroos PM, Rice AB, Zhang L, Zeldin DC, Bonner JC. Prostaglandin-E2 counteracts interleukin-1 stimulated up-regulation of platelet-derived growth factor -receptor on rat pulmonary myofibroblasts. Am J Respir Cell Mol Biol. 1999 Mar;20(3):433-40. [Abstract] [Full Text] [PDF]
  2. Gavett SH, Madison SL, Chulada P, Scarborough PE, Qu W, Boyle JE, Tiano H, Lee CA, Langenbach R, Roggli V, Zeldin DC. Allergic lung responses are increased in PGH synthase deficient mice. J Clin Invest. 1999 Sep;104(6):721-32. [Abstract] [Full Text] [PDF]
  3. Camitta MGW, Gabel SA, Chulada PC, Bradbury AJ, Langenbach R, Zeldin DC, Murphy E. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury, but are protected by acute preconditioning. Circulation. 2001 Nov 13;104(20):2453-8. [Abstract] [Full Text] [PDF]
  4. Bonner JC, Rice A, Bradbury JA, Chulada PC, Moomaw C, Morgan D, Nyska A, Tiano HF, Zeldin DC, Langenbach R. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am J Pathol. 2002 Aug;161(2):459-70. [Abstract]
  5. Carey MA, Germolec DR, Bradbury JA, Gooch RA, Moorman MP, Flake GP, Langenbach R, Zeldin DC. Accentuated T helper type 2 airway response after allergen challenge in cyclooxygenase-1-/- but not cyclooxygenase-2 -/- mice. Am J Respir Crit Care Med. 2003 Jun 1;167(11):1509-15. [Abstract] [Full Text] [PDF]
  6. Carey MA, Germolec DR, Langenbach R and Zeldin DC. (2003) Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids, 69, 157-62. [Abstract]
  7. Chulada PC, Arbes SJ, Dunson D, Zeldin DC. Breast-feeding and the prevalence of asthma and wheeze in children: Analyses from the Third National Health and Nutrition Examination Survey, 1988-1994. J Allergy Clin Immunol. 2003 Feb;111(2):328-36. [Abstract] [Full Text] [PDF]
  8. Lee CR, Zeldin DC. The Reality of Pharmacogenomics: Optimizing therapeutic decision making. Environ Health Perspect. 2003 Aug;111(11):A566-A567. [Abstract] [PDF]
  9. Carey MA, Bradbury JA, Langenbach R, Zeldin DC, Germolec DR. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol. 2005 Nov 15;175(10):6878-6884. [Abstract] [Full Text] [PDF]
  10. Card JW, Carey MA, Bradbury JA, DeGraff LM, Morgan DL, Moorman MP, Flake GP, Zeldin DC. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J Immunol. 2006 Jul 1;177(1):621-30. [Abstract] [Full Text] [PDF]
  11. Card JW, Carey MA, Bradbury JA, Graves JP, Lih FB, Moorman MP, Morgan DL, DeGraff LM, Zhao Y, Foley JF, Zeldin DC. Cyclooxygenase-1 overexpression decreases basal airway responsiveness but not allergic inflammation. J Immunol. 2006 Oct 1;177(7):4785-93. [Abstract] [Full Text] [PDF]
  12. Card JW, Voltz JW, Carey MA, Bradbury JA, DeGraff LM, Lih FB, Bonner JC, Morgan DL, Flake GP, Zeldin DC. Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol. 2007 Sep;37(3):300-8. [Abstract] [Full Text] [PDF]
  13. Lee CR, Bottone FG, Krahn J, Li L, Mohrenweiser H, Cook ME, Petrovich RM, Bell DA, Eling TE, Zeldin DC. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics. 2007 Feb;17(2):145-160. [Abstract] [Full Text] [PDF]
  14. Zeldin DC, Card JW, Carey MA, Voltz JA. Lung impedance measurements are/are not more useful than simpler measurements of lung function in animal models of pulmonary disease. J Appl Physiol. 2007 Nov;103(5):1906; author reply 1909-10. [Full Text]
  15. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L400-11. [Abstract] [Full Text]
  16. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther. 2008 Jan;83(1):52-60. [Abstract] [Full Text] [PDF]
  17. Card JW, Carey MA, Voltz JW, Bradbury JA, Ferguson CD, Cohen EA, Schwartz S, Flake GP, Morgan DL, Arbes SJ, Barrow DA, Barros SP, Offenbacher S, Zeldin DC. Modulation of allergic airway inflammation by the oral pathogen. Infect Immun. 2010 Jun;78(6):2488-96. [Abstract] [Full Text] [PDF]
  18. Carey MA, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC and Germolec DR. (2010) Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One, 5, e11610. [Abstract]
  19. Li H, Bradbury JA, Dackor RT, Edin ML, Graves JP, DeGraff LM, Wang PM, Bortner CD, Maruoka S, Lih FB, Cook DN, Tomer KB, Jetten AM and Zeldin DC. (2011) Cyclooxygenase-2 regulates Th17 cell differentiation during allergic lung inflammation. Am J Respir Crit Care Med, 184, 37-49. [Abstract]
  20. Li H, Edin ML, Bradbury JA, Graves JP, DeGraff LM, Gruzdev A, Cheng J, Dackor RT, Wang PM, Bortner CD, Garantziotis S, Jetten AM, Zeldin DC. Cyclooxygenase-2 Inhibits T Helper Cell Type 9 Differentiation during Allergic Lung Inflammation via Down-regulation of IL-17RB. American journal of respiratory and critical care medicine 2013 187(8):812-822. [Abstract]
  21. Li H, Edin ML, Gruzdev A, Cheng J, Bradbury JA, Graves JP, DeGraff LM and Zeldin DC. (2013) Regulation of T helper cell subsets by cyclooxygenases and their metabolites. Prostaglandins Other Lipid Mediat, 104-105, 74-83. [Abstract]
  22. Sayers BC, Taylor AJ, Glista-Baker EE, Shipley-Phillips JK, Dackor RT, Edin ML, Lih FB, Tomer KB, Zeldin DC, Langenbach R and Bonner JC. (2013) Role of cyclooxygenase-2 in exacerbation of allergen-induced airway remodeling by multiwalled carbon nanotubes. Am J Respir Cell Mol Biol, 49, 525-35. [Abstract]
  23. Cheng J, Dackor RT, Bradbury JA, Li H, DeGraff LM, Hong LK, King D, Lih FB, Gruzdev A, Edin ML, Travlos GS, Flake GP, Tomer KB and Zeldin DC. (2015) Contribution of alveolar type II cell-derived cyclooxygenase-2 to basal airway function, lung inflammation, and lung fibrosis. Faseb J. [Abstract]
  24. Chu CH, Chen SH, Wang Q, Langenbach R, Li H, Zeldin D, Chen SL, Wang S, Gao H, Lu RB and Hong JS. (2015) PGE2 Inhibits IL-10 Production via EP2-Mediated beta-Arrestin Signaling in Neuroinflammatory Condition. Mol Neurobiol, 52, 587-600. [Abstract]
  25. Hoopes SL, Garcia V, Edin ML, Schwartzman ML and Zeldin DC. (2015) Vascular actions of 20-HETE. Prostaglandins & other lipid mediators 120():9-16.  [Abstract]
  26. Kirkby NS, Reed DM, Edin ML, Rauzi F, Mataragka S, Vojnovic I, Bishop-Bailey D, Milne GL, Longhurst H, Zeldin DC, Mitchell JA and Warner TD. Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. Circulation 2015 29(11):4568-4578 [Abstract]
  27. Jerschow E, Edin ML, Pelletier T, Abuzeid WM, Akbar NA, Gibber M, Fried M, Lih FB, Gruzdev A, Bradbury JA, Han W, Hudes G, Keskin T, Schuster VL, Spivack S, Zeldin DC and Rosenstreich D. (2016) Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. [Abstract] 
  28. Johnson AR, Qin Y, Cozzo AJ, Freemerman AJ, Huang MJ, Zhao L, Sampey BP, Milner JJ, Beck MA, Damania B, Rashid N, Galanko JA, Lee DP, Edin ML, Zeldin DC, Fueger PT, Dietz B, Stahl A, Wu Y, Mohlke KL and Makowski L. (2016) Metabolic reprogramming through fatty acid transport protein 1 (FATP1) regulates macrophage inflammatory potential and adipose inflammation. Mol Metab, 5, 506-26. [Abstract] 

Allergen Exposure and Intervention

  1. Vojta PJ, Randels S, Stout J, Muilenberg M, Burge H, Mitchell H, O'Conner G, Zeldin DC. Effects of physical interventions on house dust mite allergen levels in carpet, bed, and upholstery dust in low-income, urban homes. Environ Health Perspect. 2001 Aug;109(8): 815-9. [Abstract]
  2. Jacobs DE, Clickner RP, Zhou JY, Viet SM, Marker DA, Rogers JW, Zeldin DC, Broene P, Friedman W. The prevalence of lead-based paint hazards in U.S. housing. Environ Health Perspect. 2002 Oct;110(10):A599-606. [Abstract] [Full Text] [PDF]
  3. Vojta PJ, Friedman W, Marker D, Clickner R, Rogers JW, Viet SM, Muilenberg ML, Burge HA, Thorne PS, Arbes SJ, Zeldin DC. First National Survey of Lead and Allergens in Housing: survey design and methods for the allergen and endotoxin components. Environ Health Perspect. 2002 May;110(5):527-32. [Abstract]
  4. Arbes SJ, Cohn R, Yin M, Muilenberg ML, Burge HA, Friedman W, Zeldin DC. House dust mite allergens in U.S. beds: Results from the First National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol. 2003 Feb;111(2):408-14. [Abstract] [Full Text]
  5. Arbes SJ, Sever M, Archer J, Long EH, Gore C, Schal C, Walter M, Neubler B, Vaughn B, Mitchell H, Liu E, Collette N, Adler P, Sandel M, Zeldin D.C. Abatement of cockroach allergen (Bla g 1) in low-income, urban housing: A randomized control trial. J Allergy Clin Immunol. 2003 Aug;112(2):339-45. [Abstract] [Full Text] [PDF]
  6. Arbes SJ, Cohn R, Yin M, Muilenberg ML, Burge HA, Friedman W, Zeldin DC. Dog allergen (Can f 1) and cat allergen (Fel d 1) in U.S. homes: Results from the National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol. 2004 Jul;114(1):111-7. [Abstract] [PDF]
  7. Arbes SJ, Sever M, Mehta J, Gore JC, Schal C, Vaughn B, Mitchell H, Zeldin DC. Abatement of cockroach allergens (Bla g 1 and Bla g 2) in low-income, urban housing: Month 12 continuation results. J Allergy Clin Immunol. 2004 Jan;113(1):109-14. [Abstract] [Full Text] [PDF]
  8. Cohn RD, Arbes SJ, Jr., Yin M, Jaramillo R and Zeldin DC. (2004) National prevalence and exposure risk for mouse allergen in US households. J Allergy Clin Immunol, 113, 1167-71. [Abstract]
  9. Arbes SJ, Jr., Gergen PJ, Elliott L and Zeldin DC. (2005) Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol, 116, 377-83. [Abstract]
  10. Arbes SJ, Sever M, Mehta J, Collette N, Thomas B and Zeldin DC. (2005) Exposure to indoor allergens in day-care facilities: results from 2 North Carolina counties. J Allergy Clin Immunol, 116, 133-9. [Abstract] [PDF]
  11. Arbes SJ, Sever M, Vaughn B, Mehta J, Lynch JT, Mitchell H, Hoppin JA, Spencer HL, Sandler DP, Zeldin DC. Feasibility of using subject-collected dust samples in epidemiologic and clinical studies of indoor allergens. Environ Health Perspect. 2005 Jun;113(6):665-9. [Abstract] [Full Text] [PDF]
  12. Pate A, Hamilton RG, Ashley PJ, Zeldin DC, Halsey JF. Proficiency testing of allergen measurements in residential dust. J Allergy Clin Immunol. 2005 Oct;116(4):844-50. [Abstract] [Full Text] [PDF]
  13. Arbes SJ, Jr., Cohn RD, Yin M, Muilenberg ML, Burge HA, Friedman W and Zeldin DC. (2003) House dust mite allergen in US beds: results from the First National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol, 111, 408-14. [Abstract]
  14. Thorne PS, Kulhankova K, Yin M, Cohn R, Arbes SJ, Jr. and Zeldin DC. (2005) Endotoxin exposure is a risk factor for asthma: the national survey of endotoxin in United States housing. Am J Respir Crit Care Med, 172, 1371-7. [Abstract]
  15. Resnick DB, Sharp R, Zeldin DC. Research on environmental health interventions: ethical problems and solutions. Account Res. 2005 Apr-Jun;12(2):69-101. [Abstract]
  16. Arbes SJ, Sever ML, Vaughn B, Cohen EA, Zeldin DC. Oral pathogens and allergic disease: Results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2006 Nov;118(5):1169-75. Epub 2006 Sep 12. [Abstract] [Full Text] [PDF]
  17. Barnes C, Portnoy J, Sever M, Arbes SJ, Vaughn B, Zeldin DC. Comparison of enzyme immunoassay-based assays for environmental alternaria alternata. Ann Allergy Asthma Immunol. 2006 Sep;97(3):350-6. [Abstract] [Full Text] [PDF]
  18. Cohn RD, Arbes SJ, Jr., Yin M, Jaramillo R and Zeldin DC. (2004) National prevalence and exposure risk for mouse allergen in US households. J Allergy Clin Immunol, 113, 1167-71. [Abstract]
  19. Cotton RB, Hazinski TA, Morrow JD, Roberts LJ, Zeldin DC, Lindstrom DP, Lappalainen U, Law AB, Steele S. Cimetidine does not prevent lung injury in newborn premature infants. Pediatr Res. 2006 Jun;59(6):795-800. [Abstract] [Full Text] [PDF]
  20. Cotton RB, Sundell H, Zeldin DC, Morrow JD, Roberts LJ, Hazinski TA, Law AB, Steele S. Inhaled nitric oxide attenuates hyperoxic lung injury in lambs. Pediatr Res. 2006 Jan;59(1):142-146.
  21. Salo, P.M., Arbes, S.J., Cohn, R.D., Burge, H.A., London, S.J. and Zeldin, D.C. Alternaria alternata antigens in U.S. homes. J Allergy Clin Immunol. 2006 Feb;117(2):473; author reply 474. [Abstract] [Full Text] [PDF]
  22. Salo PM, Arbes SJ, Sever M, Jaramillo R, Cohn RD, London SJ, Zeldin DC. Exposure to alternaria alternata in us homes is associated with asthma symptoms. J Allergy Clin Immunol. 2006 Oct;118(4):892-8. [Abstract] [Full Text] [PDF]
  23. Zeldin DC, Eggleston P, Chapman M, Piedimonte G, Renz H, Peden D. How exposures to biologics influence the induction and incidence of asthma. Environ Health Perspect. 2006 Apr;114(4):620-6. [Abstract] [Full Text] [PDF]
  24. Arbes SJ, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007 Nov;120(5):1139-45. 2007 Sep 24. [Abstract] [Full Text] [PDF]
  25. Elliott L, Arbes SJ, Harvey ES, Lee RC, Salo PM, Cohn RD, London SJ, Zeldin DC. Dust weight and asthma prevalence in the National Survey of Lead and Allergens in Housing (NSLAH). Environ Health Perspect. 2007 Feb;115(2):215-20. Epub 2006 Nov 7. [Abstract] [Full Text] [PDF]
  26. Sever ML, Arbes SJ, Jr., Gore JC, Santangelo RG, Vaughn B, Mitchell H, Schal C and Zeldin DC. (2007) Cockroach allergen reduction by cockroach control alone in low-income urban homes: a randomized control trial. J Allergy Clin Immunol, 120, 849-55. [Abstract]
  27. Yuan G, Deng J, Wang T, Zhao C, Xu X, Wang P, Voltz JW, Edin ML, Xiao X, Chao L, Chao J, Zhang XA, Zeldin DC, Wang DW. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May;148(5):2016-26. [Abstract] [Full Text] [PDF]
  28. Zeldin DC, Card JW, Carey MA, Voltz JA. Lung impedance measurements are/are not more useful than simpler measurements of lung function in animal models of pulmonary disease. J Appl Physiol. 2007 Nov;103(5):1906; author reply 1909-10. [Full Text]
  29. Zhang D, Zeldin DC, Blackshear PJ. Regulatory factor X4 variant 3: A transcription factor involved in brain development and disease. J Neurosci Res. 2007 Dec;85(16): 3515-22. [Abstract] [Full Text] [PDF]
  30. Resnik D, Zeldin D. Environmental health research on hazards in the home and the duty to warn. Bioethics 2008 May;22(4):209-217. [Abstract] [Full Text] [PDF]
  31. Salo PM, Arbes SJ, Jr., Crockett PW, Thorne PS, Cohn RD and Zeldin DC. (2008) Exposure to multiple indoor allergens in US homes and its relationship to asthma. J Allergy Clin Immunol, 121, 678-684 e2. [Abstract]
  32. Fessler MB, Massing MW, Spruell B, Jaramillo R, Draper DW, Madenspacher JH, Arbes SJ, Calatroni A, Zeldin DC. Novel relationship of serum cholesterol with asthma and wheeze in the United States. J Allergy Clin Immunol. 2009 Nov;124(5):967-74.e1-15. 2009 Oct 3. [Abstract]
  33. Gergen PJ, Arbes SJ, Calatroni A, Mitchell HE, Zeldin DC. Total IgE and asthma prevalence in the U.S. population: Results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006. J Allergy Clin Immunol. 2009 Sep;124(3):447-53. 2009 Aug 3. [Abstract] [Full Text] [PDF]
  34. Salo PM, Jaramillo R, Cohn RD, London SJ and Zeldin DC. (2009) Exposure to mouse allergen in U.S. homes associated with asthma symptoms. Environ Health Perspect, 117, 387-91. [Abstract]
  35. Salo PM, Sever ML and Zeldin DC. (2009) Indoor allergens in school and day care environments. J Allergy Clin Immunol, 124, 185-92, 192 e1-9; quiz 193-4. [Abstract]
  36. Salo PM, Zeldin DC. Does exposure to cats and dogs decrease the risk of developing allergic sensitization and disease? J Allergy Clin Immunol. 2009 Oct;124(4):751-2. [Abstract] [Full Text] [PDF]
  37. Thorne PS, Cohn RD, Mav D, Arbes SJ and Zeldin DC. (2009) Predictors of endotoxin levels in U.S. housing. Environ Health Perspect, 117, 763-71. [Abstract]
  38. Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz AM, Liu AH, Calatroni A and Zeldin DC. (2009) Association of obesity with IgE levels and allergy symptoms in children and adolescents: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol, 123, 1163-9, 1169 e1-4. [Abstract]
  39. Fessler MB, Jaramillo R, Crockett PW, Zeldin DC. Relationship of serum cholesterol levels to atopy in the U.S. population. Allergy. 2010 Jul;65(7):859-64. 2009 Dec 16. [Abstract] [Full Text] [PDF]
  40. Krieger J, Jacobs DE, Ashley PJ, Bzaeder A, Chew GL, Dearborn D, Hynes HP, Miller JD, Morley R, Rabito F, Zeldin DC. Housing interventions and control of asthma-related indoor biologic agents: A review of the evidence. J Public Health Manag Pract. 2010 Sep-Oct;16(5 Suppl):S11-20. [Abstract] [Full Text] [PDF]
  41. Liu AH, Jaramillo R., Sicherer SH, Wood RA, Bock SA, Burks AW, Massing M, Cohn RD, Zeldin DC. National Prevalence and Risk Factors for Food Allergy and Relationship to Asthma: Results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2010 126: 798-806. [Abstract]
  42. Salo PM and Zeldin DC. (2010) Cats and dogs: an attractive remedy versus atopy? J Allergy Clin Immunol, 125, 765-6. [Abstract]
  43. Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz AM, Calatroni A, Zeldin DC. Association of Childhood Obesity with Atopic and Non-Atopic Asthma: Results from the National Health and Nutrition Examination Survey 1999-2006. J Asthma. 2010 47(7):822-829. [Abstract]
  44. Hoppin JA, Jaramillo R, Salo P, Sandler DP, London SJ, Zeldin DC. Questionnaire predictors of atopy in a U.S. population sample: Findings from the National Health and Nutrition Examination Survey, 2005-2006. Am J Epidemiol. 2011 173:544-552. [Abstract]
  45. Salo PM, Calatroni A, Gergen PJ, Hoppin JA, Sever ML, Jaramillo R, Arbes SJ, Zeldin DC. Allergy-related outcomes in relation to serum IgE: Results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2011 127(5):1226-1235.e7. [Abstract]
  46. Sever ML, Salo PM, Haynes AK, Zeldin DC. Inner-city environments and mitigation of cockroach allergen. Am J Prev Med. 2011 41:S55-56. [Full Text]
  47. Wilson RH, Maruoka S, Whitehead GS, Foley JF, Flake GP, Sever ML, Zeldin DC, Kraft M, Garantziotis S, Nakano H and Cook DN. (2012) The Toll-like receptor 5 ligand flagellin promotes asthma by priming allergic responses to indoor allergens. Nat Med, 18, 1705-10. [Abstract]
  48. Busse PJ, Cohn RD, Salo PM and Zeldin DC. (2013) Characteristics of allergic sensitization among asthmatic adults older than 55 years: results from the National Health and Nutrition Examination Survey, 2005-2006. Ann Allergy Asthma Immunol, 110, 247-52. [Abstract]
  49. Hoppin JA, Jaramillo R, London SJ, Bertelsen RJ, Salo PM, Sandler DP and Zeldin DC. (2013) Phthalate exposure and allergy in the U.S. population: results from NHANES 2005-2006. Environ Health Perspect, 121, 1129-34. [Abstract]
  50. Jaramillo R, Cohn RD, Crockett PW, Gowdy KM, Zeldin DC, Fessler MB. Relation between objective measures of atopy and myocardial infarction in the United States. Journal of Allergy and Clinical Immunology 2013 131(2):405-411. [Abstract]
  51. Jaramillo R, Cohn RD, Crockett PW, Gowdy KM, Zeldin DC, Fessler MB. Relation between objective measures of atopy and myocardial infarction in the United States. Journal of Allergy and Clinical Immunology 2013 131(2):405-411. [Abstract]
  52. King EM, Filep S, Smith B, Platts-Mills T, Hamilton RG, Schmechel D, Sordillo JE, Milton D, van Ree R, Krop EJ, Heederik DJ, Metwali N, Thorne PS, Zeldin DC, Sever ML, Calatroni A, Arbes SJ, Jr., Mitchell HE and Chapman MD. (2013) A multi-center ring trial of allergen analysis using fluorescent multiplex array technology. J Immunol Methods, 387, 89-95. [Abstract]
  53. Weir CH, Yeatts KB, Sarnat JA, Vizuete W, Salo PM, Jaramillo R, Cohn RD, Chu H, Zeldin DC, London SJ. Nitrogen dioxide and allergic sensitization in the 2005-2006 National Health and Nutrition Examination Survey. Respir Med. 2013 107(11):1763-72. [Abstract]
  54. Hoppin JA, Umbach DM, Long S, Rinsky JL, Henneberger PK, Salo PM, Zeldin DC, London SJ, Alavanja MC, Blair A, Beane Freeman LE, Sandler DP. Respiratory disease in United States farmers. Occupational and environmental medicine. 2014 71(7):484-491. [Abstract]
  55. Parks CG, Miller FW, Satoh M, Chan EK, Andrushchenko Z, Birnbaum LS, Jusko TA, Kissling GE, Patel MD, Rose KM, Weinberg C, Zeldin DC and Sandler DP. (2014) Reproductive and hormonal risk factors for antinuclear antibodies (ANA) in a representative sample of U.S. women. Cancer Epidemiol Biomarkers Prev, 23, 2492-502. [Abstract]
  56. Salo PM, Arbes SJ, Jr., Jaramillo R, Calatroni A, Weir CH, Sever ML, Hoppin JA, Rose KM, Liu AH, Gergen PJ, Mitchell HE and Zeldin DC. (2014) Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006. J Allergy Clin Immunol, 134, 350-9. [Abstract]
  57. Dinse GE, Jusko TA, Whitt IZ, Co CA, Parks CG, Satoh M, Chan EK, Rose KM, Walker NJ, Birnbaum LS, Zeldin DC, Weinberg CR and Miller FW. (2015) Associations between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999-2004. Environ Health Perspect. [Abstract]
  58. Hernandez-Cadena L, Zeldin DC, Barraza-Villarreal A, Sever ML, Sly PD, London SJ, Escamilla-Nunez MC and Romieu I. (2015) Indoor determinants of dustborne allergens in Mexican homes. Allergy Asthma Proc, 36, 130-7. [Abstract]
  59. Thorne PS, Mendy A, Metwali N, Salo P, Co C, Jaramillo R, Rose KM and Zeldin DC. (2015) Endotoxin Exposure: Predictors and Prevalence of Associated Asthma Outcomes in the U.S. Am J Respir Crit Care Med. [Abstract]
  60. Winn AK, Salo PM, Klein C, Sever ML, Zombeck A, Harris SF , Johndrow D , Crockett PW, Cohn RD , ZeldinDC. (2016) Efficacy of an in-home test kit in reducing dust mite allergen levels: results of a randomized controlled pilot study. The Journal of asthma: official journal of the Association for the Care of Asthma 53(2):133-138. [Abstract]
  61. Dinse GE, Jusko TA , Whitt IZ , Co CA, Parks CG, Satoh M, Chan EKL, Rose KM, Walker NJ, Birnbaum LS, Zeldin DC, Weinberg CR , Miller FW. Associations Between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999-2004. Environmental health perspectives 2016 124(4):426-436. [Abstract]
  62. McGowan EC, Matsui EC, Peng R, Salo PM, Zeldin DC and Keet CA. (2016) Racial/ethnic and socioeconomic differences in self-reported food allergy among food-sensitized children in National Health and Nutrition Examination Survey III. Ann Allergy Asthma Immunol, 117, 570-572 e3. [Abstract] 
  63. McGowan EC, Peng RD, Salo PM, Zeldin DC and Keet CA. (2016) Changes in Food-Specific IgE Over Time in the National Health and Nutrition Examination Survey (NHANES). J Allergy Clin Immunol Pract, 4, 713-20. [Abstract] 
  64. Roux M, Devillier P, Yang WH, Montagut A, Abiteboul K, Viatte A and Zeldin RK. (2016) Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. J Allergy Clin Immunol, 138, 451-458 e5. [Abstract] 
  65. Gold DR, Adamkiewicz G, Arshad SH, Celedon JC, Chapman MD, Chew GL, Cook DN, Custovic A, Gehring U, Gern JE, Johnson CC, Kennedy S, Koutrakis P, Leaderer B, Mitchell H, Litonjua AA, Mueller GA, O'Connor GT, Ownby D, Phipatanakul W, Persky V, Perzanowski MS, Ramsey CD, Salo PM, Schwaninger JM, Sordillo JE, Spira A, Suglia SF, Togias A, Zeldin DC and Matsui EC. (2017) NIAID, NIEHS, NHLBI, MCAN Workshop Report: The Indoor Environment and Childhood Asthma: Implications for Home Environmental Intervention in Asthma Prevention and Management. J Allergy Clin Immunol. [Abstract] 

Other Studies

  1. Zeldin DC, Corcia A and Armstrong WM. (1985) Cyclic AMP-induced changes in membrane conductance of Necturus gallbladder epithelial cells. J Membr Biol, 84, 193-206. [Abstract]
  2. Zhao C, Wang P, Xiao X, Chao J, Chao L, Wang DW and Zeldin DC. (2003) Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension, 42, 1026-33. [Abstract]
  3. Blackshear PJ, Graves JP, Stumpo DJ, Cobos I, Rubenstein JL and Zeldin DC. (2003) Graded phenotypic response to partial and complete deficiency of a brain-specific transcript variant of the winged helix transcription factor RFX4. Development, 130, 4539-52. [Abstract]
  4. Lee CR, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Coresh J, Folsom AR, Boerwinkle E, Heiss G, Zeldin DC. NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: The Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics. 2006 Dec;16(12):891-899. [Abstract] [Full Text]
  5. Zhang D, Stumpo DJ, Graves JP, DeGraff LM, Grissom SF, Collins JB, Li L, Zeldin DC and Blackshear PJ. (2006) Identification of potential target genes for RFX4_v3, a transcription factor critical for brain development. J Neurochem, 98, 860-75. [Abstract]
  6. Yuan G, Deng J, Wang T, Zhao C, Xu X, Wang P, Voltz JW, Edin ML, Xiao X, Chao L, Chao J, Zhang XA, Zeldin DC, Wang DW. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May;148(5):2016-26. [Abstract] [Full Text] [PDF]
  7. 7. Card JW, Voltz JW, Ferguson CD, Carey MA, DeGraff LM, Peddada SD, Morgan DL and Zeldin DC. (2007) Male sex hormones promote vagally mediated reflex airway responsiveness to cholinergic stimulation. Am J Physiol Lung Cell Mol Physiol, 292, L908-14. [Abstract]
  8. Carey MA, Card JW, Bradbury JA, Moorman MP, Haykal-Coates N, Gavett SH, Graves JP, Walker VR, Flake GP, Voltz JW, Zhu D, Jacobs ER, Dakhama A, Larsen GL, Loader JE, Gelfand EW, Germolec DR, Korach KS and Zeldin DC. (2007) Spontaneous airway hyperresponsiveness in estrogen receptor-alpha-deficient mice. Am J Respir Crit Care Med, 175, 126-35. [Abstract]
  9. Carey MA, Card JW, Voltz JW, Arbes SJ, Jr., Germolec DR, Korach KS and Zeldin DC. (2007) It's all about sex: gender, lung development and lung disease. Trends Endocrinol Metab, 18, 308-13. [Abstract]
  10. Carey MA, Card JW, Voltz JW, Germolec DR, Korach KS, Zeldin DC. The impact of sex and sex hormones on lung physiology and disease: Lessons from animal studies. Am J Physiol Lung Cell Mol Physiol. 2007 Aug;293(2):L272-8. [Abstract] [Full Text]
  11. Zhang D, Zeldin DC, Blackshear PJ. Regulatory factor X4 variant 3: A transcription factor involved in brain development and disease. J Neurosci Res. 2007 Dec;85(16): 3515-22. [Abstract] [Full Text] [PDF]
  12. Tu L, Xu X, Wan H, Zhou C, Deng J, Xu G, Xiao W, Xiao X, Chen Y, Edin ML, Voltz JW, Zeldin DC, Wang DW. Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther. 2008 Apr;19(4):318-30. [Abstract] [Full Text] [PDF]
  13. Voltz JW, Card JW, Carey MA, DeGraff LM, Ferguson CD, Flake GP, Bonner JC, Korach KS, Zeldin DC. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008 Jul;39(1):45-52. [Abstract] [Full Text] [PDF]
  14. Zhang D, Harry JG, Blackshear PJ, Zeldin DC. G-protein pathway suppressor 2 (GPS2) interacts with the regulatory factor X4 variant 3 (RFX4_v3) and functions as a transcriptional co-activator. Journal Biol Chem. 2008 Mar 28;283(13):8580-90. [Abstract] [Full Text]
  15. Bonner JC, Card JW, Zeldin DC. Nanoparticle-mediated drug delivery and pulmonary hypertension. Hypertension. 2009 May;53(5):751-3. [Abstract] [Full Text] [PDF]
  16. Chung WC, Ryu SH, Sun H, Zeldin DC and Koo JS. (2009) CREB mediates prostaglandin F2alpha-induced MUC5AC overexpression. J Immunol, 182, 2349-56. [Abstract]
  17. Card JW, Zeldin DC. Hormonal influences on lung function and response to environmental agents: Lessons from animal models of respiratory disease. Proc Am Thorac Soc. 2009 Dec 1;6(7):588-95. [Abstract]
  18. Guan H, Wang P, Hui R, Edin ML, Zeldin DC, Wang DW. Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem. 2009 Feb;55(2):274-84. [Abstract] [Full Text] [PDF]
  19. Zhao CX, Xu X, Cui Y, Wang P, Wei X, Yang S, Edin ML, Zeldin DC, Wang DW. Increased endothelial nitric-oxide synthase expression reduces hypertension and hyperinsulinemia in fructose-treated rats. J. Pharmacol. Exp. Ther. 2009 Feb;328(2):610-20. [Abstract] [Full Text] [PDF]
  20. Chulada PC, Vainorius E, Garantziotis S, Burch L, Blackshear PJ, Zeldin DC. The Environmental Polymorphism Registry – a unique resource that facilitates translational research of environmental disease. Environmental Health Perspectives. 2011 119(11):1523-1527. [Abstract]
  21. Thomas AC, Nouls JC, Driehuys B, Voltz JW, Fubara B, Foley J, Bradbury JA and Zeldin DC. (2011) Ventilation defects observed with hyperpolarized 3He magnetic resonance imaging in a mouse model of acute lung injury. Am J Respir Cell Mol Biol, 44, 648-54. [Abstract]
  22. Li X, Yang G, Zhao G, Wu B, Edin ML, Zeldin DC, Wang DW. Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Hypertension Research. 2011 34: 869-875. [Abstract]
  23. Birnbaum LS, Bucher JR, Collman GW, Zeldin DC, Johnson AF, Schug TT and Heindel JJ. (2012) Consortium-based science: the NIEHS's multipronged, collaborative approach to assessing the health effects of bisphenol A. Environ Health Perspect, 120, 1640-4. [Abstract]
  24. Marczak ED, Marzec J, Zeldin DC, Kleeberger SR, Brown NJ, Pretorius M and Lee CR. (2012) Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans. Pharmacogenet Genomics, 22, 620-8. [Abstract]
  25. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, Jusko TA, Walker NJ, Germolec DR, Whitt IZ, Crockett PW, Pauley BA, Chan JY, Ross SJ, Birnbaum LS, Zeldin DC and Miller FW. (2012) Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum, 64, 2319-27. [Abstract]
  26. Yildirim E, Carey MA, Card JW, Dietrich A, Flake GP, Zhang Y, Bradbury JA, Rebolloso Y, Germolec DR, Morgan DL, Zeldin DC and Birnbaumer L. (2012) Severely blunted allergen-induced pulmonary Th2 cell response and lung hyperresponsiveness in type 1 transient receptor potential channel-deficient mice. Am J Physiol Lung Cell Mol Physiol, 303, L539-49. [Abstract]
  27. Fessler MB, Rose K, Zhang Y, Jaramillo R and Zeldin DC. (2013) Relationship between serum cholesterol and indices of erythrocytes and platelets in the US population. J Lipid Res, 54, 3177-88. [Abstract]
  28. Kim JM, Kosak JP, Kim JK, Kissling G, Germolec DR, Zeldin DC, Bradbury JA, Baek SJ and Eling TE. (2013) NAG-1/GDF15 transgenic mouse has less white adipose tissue and a reduced inflammatory response. Mediators Inflamm, 2013, 641851. [Abstract]
  29. Trivedi DB, Loftin CD, Clark J, Myers P, DeGraff LM, Cheng J, Zeldin DC and Langenbach R. (2013) beta-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice. Circ Res, 112, 1219-29. [Abstract]
  30. House JS, Li H, DeGraff LM, Flake G, Zeldin DC, London SJ. Genetic variation in HTR4 and lung function: GWAS follow-up in mouse. FASEB J. 2015;29:323-35. PMID: 25342126. [Abstract] [Full Text]
  31. Qiu LQ, Lai WS, Bradbury A, Zeldin DC and Blackshear PJ. (2015) Tristetraprolin (TTP) coordinately regulates primary and secondary cellular responses to proinflammatory stimuli. J Leukoc Biol, 97, 723-36. [Abstract]
  32. Lee CR and Zeldin DC. (2015) Resolvin Infectious Inflammation by Targeting the Host Response. N Engl J Med, 373, 2183-5. [Abstract] 
  33. House JS, Nichols CE, Li H, Brandenberger C, Virgincar RS, DeGraff LM, Driehuys B, Zeldin DC and London SJ. (2017) Vagal innervation is required for pulmonary function phenotype in Htr4-/- mice. Am J Physiol Lung Cell Mol Physiol, 312, L520-L530. [Abstract] 
Back
to Top